Intravitreous Bevacizumab Treatment for Macular Edema due to Central Retinal Vein Occlusion

REFERENCES

• Rogers S, McIntosh RL, Cheung N et al. International Eye Disease Consortium. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology 2010;117:313–9.e1.
   PubMed Web of Science ®Google Scholar
• Cugati S, Wang JJ, Rochtchina E et al. Ten-year incidence of retinal vein occlusion in an older population: the Blue Mountains Eye Study. Arch Ophthalmol 2006;124:726–732.
   PubMed Web of Science ®Google Scholar
• Aiello LP, Avery RL, Arrigg PG et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994;331:1480–1487.
   PubMed Web of Science ®Google Scholar
• Park SP, Ahn JK, Mun GH. Aqueous vascular endothelial growth factor levels are associated with serous macular detachment secondary to branch retinal vein occlusion. Retina (Philadelphia, Pa) 2010;30:281–286.
   PubMed Web of Science ®Google Scholar
• Noma H, Funatsu H, Mimura T et al. Role of soluble vascular endothelial growth factor receptor-2 in macular oedema with central retinal vein occlusion. Br J Ophthalmol 2011;95:788–792.
   PubMed Web of Science ®Google Scholar
• Kim JY, Park SP. Comparison between intravitreal bevacizumab and triamcinolone for macular edema secondary to branch retinal vein occlusion. Korean J Ophthalmol 2009;23:259–265.
   Google Scholar
• Stahl A, Struebin I, Hansen LL et al. Bevacizumab in central retinal vein occlusion: a retrospective analysis after 2 years of treatment. Eur J Ophthalmol 2010;20:180–185.
   PubMed Web of Science ®Google Scholar
• Hung KH, Lee SM, Lee SY et al. Intravitreal bevacizumab (avastin) in the treatment of macular edema associated with perfused retinal vein occlusion. J Ocul Pharmacol Ther 2010;26:85–90.
   Google Scholar
• Wu WC, Cheng KC, Wu HJ. Intravitreal triamcinolone acetonide vs bevacizumab for treatment of macular oedema due to central retinal vein occlusion. Eye (Lond) 2009;23:2215–2222.
   PubMed Web of Science ®Google Scholar
• Tao Y, Hou J, Jiang YR et al. Intravitreal bevacizumab vs triamcinolone acetonide for macular oedema due to central retinal vein occlusion. Eye (Lond) 2010;24:810–815.
   PubMedGoogle Scholar
• Chang LK, Spaide RF, Klancnik JM et al. Longer-term outcomes of a prospective study of intravitreal ranibizumab as a treatment for decreased visual acuity secondary to central retinal vein occlusion. Retina (Philadelphia, Pa) 2011;31:821–828.
   Google Scholar
• Brown DM, Campochiaro PA, Singh RP et al. CRUISE Investigators. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 2010;117:1124–1133.e1.
   PubMed Web of Science ®Google Scholar
• Bressler NM, Schachat AP. Management of macular edema from retinal vein occlusions: you can never have too many choices. Ophthalmology 2010;117:1061–1063.
   PubMedGoogle Scholar
• Wolf-Schnurrbusch UE, Ceklic L, Brinkmann CK et al. Macular thickness measurements in healthy eyes using six different optical coherence tomography instruments. Invest Ophthalmol Vis Sci 2009;50:3432–3437.
   PubMed Web of Science ®Google Scholar
• Krebs I, Hagen S, Smretschnig E, et al. Conversion of Stratus optical coherence tomography (OCT) retinal thickness to Cirrus OCT values in age-related macular degeneration. Br J Ophthalmol (In Press).
   Google Scholar
• Chopovska Y, Jaeger M, Rambow R et al. Comparison of central retinal thickness in healthy children and adults measured with the Heidelberg Spectralis OCT and the zeiss Stratus OCT 3. Ophthalmologica 2011;225:27–36.
   Google Scholar
• Spaide RF. Peripheral areas of nonperfusion in treated central retinal vein occlusion as imaged by wide-field fluorescein angiography. Retina (Philadelphia, Pa) 2011;31:829–837.
   PubMed Web of Science ®Google Scholar
• Ip MS, Scott IU, VanVeldhuisen PC et al. SCORE Study Research Group. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. Arch Ophthalmol 2009;127:1101–1114.
   PubMed Web of Science ®Google Scholar
• Haller JA, Bandello F, Belfort R Jr et al. OZURDEX GENEVA Study Group. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 2010;117:1134–1146.e3.
   PubMed Web of Science ®Google Scholar
• Kinge B, Stordahl PB, Forsaa V et al. Efficacy of ranibizumab in patients with macular edema secondary to central retinal vein occlusion: results from the sham-controlled ROCC study. Am J Ophthalmol 2010;150:310–314.
   PubMed Web of Science ®Google Scholar
• Algvere PV, Von Wendt G, Gudmundsson J et al. Visual improvement in central retinal vein occlusion (CRVO) following intravitreal injections of bevacizumab (Avastin®). Acta Ophthalmol 2010;88:836–841.
   PubMed Web of Science ®Google Scholar
• Ach T, Hoeh AE, Schaal KB et al. Predictive factors for changes in macular edema in intravitreal bevacizumab therapy of retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2010;248:155–159.
   PubMed Web of Science ®Google Scholar
• Ehrlich R, Ciulla TA, Moss AM et al. Combined treatment of intravitreal bevacizumab and intravitreal triamcinolone in patients with retinal vein occlusion: 6 months of follow-up. Graefes Arch Clin Exp Ophthalmol 2010;248:375–380.
   Google Scholar
• Zhang H, Liu ZL, Sun P et al. Intravitreal bevacizumab for treatment of macular edema secondary to central retinal vein occlusion: eighteen-month results of a prospective trial. J Ocul Pharmacol Ther 2011;27:615–621.
   Google Scholar
• DeCroos FC, Ehlers JP, Stinnett S et al. Intravitreal bevacizumab for macular edema due to central retinal vein occlusion: perfused vs. ischemic and early vs. late treatment. Curr Eye Res 2011;36:1164–1170.
   PubMed Web of Science ®Google Scholar
• Algvere PV, Epstein D, von Wendt G et al. Intravitreal bevacizumab in central retinal vein occlusion: 18-month results of a prospective clinical trial. Eur J Ophthalmol 2011;21:789–795.
   PubMed Web of Science ®Google Scholar
• Guthoff R, Meigen T, Hennemann K et al. Comparison of bevacizumab and triamcinolone for treatment of macular edema secondary to central retinal vein occlusion – a matched-pairs analysis. Ophthalmologica 2010;224:126–132.
   PubMedGoogle Scholar